Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

**Introduction:** Primary myelofibrosis (MF) is a rare hematologic disease belonging to the group of Philadelphia-negative chronic myeloproliferative neoplasms. Identification of the Janus Kinase (JAK) gene mutations inaugurated a new era in the targeted therapy of myeloproliferative diseases. Ruxol...

Full description

Saved in:
Bibliographic Details
Main Authors: María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, Rudi Subirá
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2017-11-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9808
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items